TRMT112 and cancer: It has been reported that METTL5/TRMT112 and its mediated m6A modification of 18S rRNA 1832 site (m6A1832) are increased in NPC, promoting tumour occurrence and resistance to chemotherapy, suggesting that METTL5 targeted inhibition agent has the potential to act as a synergistic rRNA modification and mRNA modification agent to treat cancer.102